.avif)
.avif)
Acadia Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
San Diego, CA, USA
Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative treatments for neurological disorders and rare diseases worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@acadia-pharm.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1993
Headquarters
San Diego, CA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Website
Key Executives
Catherine Owen Adams (Chief Executive Officer), Mark C. Schneyer (Executive Vice President, Chief Financial Officer), Scott Cenci (Senior Vice President, Chief Information and Data Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Acadia Pharmaceuticals?
Acadia Pharmaceuticals uses the first.last format on acadia.com, so Jane Smith would be jane.smith@acadia.com.
What approved medicines does Acadia Pharmaceuticals currently market?
Acadia Pharmaceuticals markets two FDA-approved medicines: NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
Where is Acadia Pharmaceuticals headquartered and how large is the company?
Acadia Pharmaceuticals is headquartered in San Diego, CA, and has approximately 1,005 employees. If you need to reach a specific contact there, a tool like Clay can help verify email addresses and enrich employee records quickly.
Which neurological and rare disease areas is Acadia Pharmaceuticals targeting with its pipeline?
Acadia Pharmaceuticals is advancing pipeline programs across Alzheimer's disease psychosis, Lewy body dementia with psychosis, major depressive disorder, essential tremor, tardive dyskinesia, Huntington's disease, Fragile X syndrome, and SYNGAP1, a rare genetic neurodevelopmental condition.
Who leads Acadia Pharmaceuticals as Chief Executive Officer?
Catherine Owen Adams serves as Chief Executive Officer of Acadia Pharmaceuticals. Mark C. Schneyer is the Executive Vice President and Chief Financial Officer, and Scott Cenci holds the role of Senior Vice President and Chief Information and Data Officer.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating